T he optimal adrenergic support in shock is controversial. Dopamine and norepinephrine are the most commonly used agents to restore tissue perfusion pressure in these conditions. Although dopamine is the natural precursor of norepinephrine, and both combine ␣-and ␤-adrenergic properties, they are different molecules and have different pharmacologic profiles. Dopamine has relatively stronger ␤ 1 -adrenergic properties, thus increasing myocardial contractility more than norepinephrine, which has relatively stronger ␣-adrenergic properties and thus increases arterial pressure and systemic vascular resistance more than dopamine.
Both have their advantages and potential disadvantages, although many of the suggested effects of vasopressors have not been demonstrated in humans, particularly in those with critical illness. Dopamine is more likely to increase cardiac output and may also preferentially distribute blood flow to the splanchnic and renal vasculature by its additional dopaminergic properties (1, 2) . Dopamine may have beneficial effects on diaphragmatic function (3) and on the resorption of edema fluid (4, 5) . However, it may increase heart rate and can produce tachyarrhythmias. Dopamine may also suppress pituitary function, particularly prolactin secretion (6) .
Norepinephrine is a more potent vasoconstrictor, through its potent ␣ 1 stimulation with moderate ␤ 1 and minimal ␤ 2 activity. Norepinephrine was found to be more effective than dopamine in restoring hemodynamic stability and even sometimes urine output in patients with sepsis (7) . Concerns with the use of norepinephrine are the potential risks of excessive vasoconstriction and decreased organ perfusion. However, the combination of norepinephrine with dobutamine may counteract this effect (8) .
In a large cohort of European intensive care unit (ICU) patients included in the Sepsis Occurrence in Critically Ill Patients (SOAP) study, we determined whether dopamine administration was associated with a poor outcome in patients with shock due to any cause and in a subgroup of septic shock patients, and we identified other factors associated with a poor outcome in these patients. Although the study was purely observational, multivariate analyses can help to identify important factors.
METHODS
Study Design. This report is the result of a substudy from the SOAP database: a prospective, multiple-center, observational study that was designed to evaluate the epidemiology of sepsis in European countries and was initiated by a working group of the European Society of Intensive Care Medicine. Institutional recruitment for participation was by open invitation from the study steering committee to European ICUs. Since this epidemiologic, observational study did not require any deviation from routine medical practice, institutional review board approval was either waived or expedited in participating institutions and informed consent was not required. We included all adult patients (Ͼ15 yrs) admitted to the participating centers (see the Appendix for a list of participating countries and centers) between May 1 and May 15, 2002 . Patients were followed up until death or hospital discharge or for 60 days. Those who stayed in the ICU for Ͻ24 hrs for routine postoperative observation, and patients with burns, were excluded.
Data Management. Data were collected prospectively using preprinted case report forms. Detailed instructions, explaining the aim of the study, instructions for data collection, and definitions for various important items were available for all participants through an Internet-based Web site before starting data collection and throughout the study period. The steering committee maintained continuous contact with the investigators and processed all queries during data collection.
Data were entered centrally by medical personnel using the SPSS version 11.0 for Windows (SPSS, Chicago, IL) . A random sample of 5% of data was reentered by a different encoder and revised by a third; a consistency of Ͼ99.5% per variable and 98.5% per patient was observed during the whole process of data entry. In case of inconsistency, data were verified and corrected. Daily frequency tables were reviewed for all variables, and the investigators were queried when data values either were questionable or were missing for required fields. There was no data quality control at the data collection level. Data collection on admission included demographic data and comorbid diseases. Clinical and laboratory data for Simplified Acute Physiology Score (SAPS) II (9) were reported as the worst value within 24 hrs after admission. Microbiological and clinical infections were reported daily as (10) was performed, with the most abnormal value for each of the six organ systems (i.e., respiratory, renal, cardiovascular, hepatic, coagulation, and neurologic) being collected on admission and every 24 hrs thereafter. For a single missing value, a replacement was calculated using the mean value of the results on either side of the absent result. If the first or the last value was missing, the nearest value was carried backward or forward, respectively. When more than one consecutive result was missing, it was considered to be a missing value in the analysis. Missing data represented Ͻ6% of the total collected study data, of which only 2% were replaced.
Missing data in the current analysis (patients with shock) represented Ͻ1% of the overall variables. Only 28 patients had one or more missing value. Infection was defined as the presence of a pathogenic microorganism and/or clinical infection necessitating antibiotic administration, and ICU-acquired infection was defined as infection occurring Ն48 hrs after ICU admission. Circulatory shock was defined as a cardiovascular SOFA score Ͼ2 (the need for vasopressor agents, i.e., dopamine Ͼ5 g/kg/min, or epinephrine or norepinephrine any dose), and septic shock was defined as the association of shock and infection (11) . Fluid balance was calculated during the shock episode: the cumulative fluid balance as the sum of daily fluid balance, and the mean fluid balance as the cumulative fluid balance in liters divided by the number of days in shock. Statistical Methods. Data were analyzed using SPSS 11.0 for Windows. Descriptive statistics were computed for all study variables. Kolmogoroff-Smirnov test was used to verify the normality of distribution of continuous variables. Nonparametric measures of comparison were used for variables evaluated as not normally distributed. Difference testing between groups was performed using the twotailed Student's t-test, Mann-Whitney U test, chi-square test, and Fisher's exact test as appropriate. We performed a multivariable, forward stepwise, logistic regression analysis with ICU outcome as the dependent variable in patients with shock due to any cause and in patients with septic shock. Variables considered for the multivariable analysis included age, gender, comorbid diseases and SAPS II score on admission, the extent of organ failure assessed by the SOFA score, the initial and maximum dose of vasopressors, and the mean fluid balance. Variables were introduced in the multivariate model if significantly associated with a higher risk of ICU mortality on a univariate basis at p Ͻ 0.2. Colinearity between variables was excluded before modeling by computing the correlation of estimates, with an R 2 Ͼ .7 considered to be significant. Interaction terms involving combinations between comorbid diseases on admission and between various catecholamines were tested. After adjustment for demographic variables, comorbidities on admission, severity scores, and fluid balance, the initial and the maximum doses of each agent were injected in the model in a stepwise fashion. Three countries were associated with higher and one with lower ICU mortalities in comparison with other countries and were adjusted for in the final model. The use of each catecholamine was introduced in the last step as a categorical variable. A Hosmer and Lemeshow goodness-of-fit test was performed; Nagelkerke pseudo R 2 , classification tables, and odds ratios with 95% confidence interval were computed. Kaplan-Meier survival curves were plotted and compared using a signed log rank test. To minimize the effect of censored data in the survival analysis, we considered 30-day survival as a target. All statistics were two-tailed, and a p Ͻ .05 was considered to be significant.
RESULTS
Of the 3,147 patients included in the SOAP study, 1,058 (33.6%) had shock at any time; 462 (14.7%) had septic shock. Among 198 contributing centers, 101 (1,719 patients) were university, 64 (879 patients) city, and 33 (549 patients) community hospitals. The incidence of shock due to any cause (25.5%, 34.2%, and 35.9%, respectively, p Ͻ .001) and septic shock (10.6%, 14.9%, and 15.9%, respectively, p ϭ .004) was lower in community compared with city and university hospitals.
Catecholamine Use. Norepinephrine was the most commonly used vasopressor agent (80.2%), used as a single agent in 31.8% of patients with shock. Dopamine was used in 35.4% of patients with shock, as a single agent in 8.8% of patients and combined most commonly with norepinephrine (11.6%). Epinephrine was used less commonly (23.3%) but rarely as a single agent (4.5%). Dobutamine was combined with other catecholamines in 33.9% of patients, mostly with norepinephrine (15.4%). All four catecholamines were administered simultaneously in 2.6% of patients (Table 1) . Other, less commonly used vasoactive/inotropic drugs included dopexamine (n ϭ 16), vasopressin (n ϭ 11), isoproterenol (n ϭ 9), milrinone (n ϭ 9), and phenylephrine (n ϭ 5).
Among patients with shock, 375 patients (35.4%) received dopamine (dopamine group) and 683 (64.6%) did not (Table 2) . Age, gender, SAPS II score, SOFA score, and infection rates on admission were comparable between dopamine groups and other patients in shock. The dopamine group had a higher incidence of chronic obstructive pulmonary disease and heart failure. The maximum dose of dopamine administered per patient was 8.5 (5.5-13. 3) g/kg/min (median [interquartile range]). Of the 375 patients who received dopamine, 290 (77.3%) received doses of Ͼ5 g/kg/min, 42 (11.2%) received 3-5 g/kg/min, and 43 (11.5%) received Ͻ3 g/kg/min (in conjunction with either epinephrine or norepinephrine). Dopamine was used more in community than in university or city hospitals (43.6%, 36.3%, and 29.9%, respectively, p ϭ .016). There was substantial international variability in the use of vasopressors (Fig. 1) .
Morbidity and Mortality. ICU and hospital mortality rates were higher in patients with shock due to any cause (38.3% vs. 8.5% and 44.6% vs. 13.6%, respectively, both p Ͻ .01) than in patients without shock, and higher in patients with septic than nonseptic shock (47.4% vs. 31.2% and 54.1% vs. 37.2%, respectively, both p Ͻ .01). ICU mortality rate in patients with shock was similar among university, city, and community hospitals (39.4%, 38.9%, and 32.1%, respectively, p ϭ .273). Patients treated with dopamine had higher ICU, 30-day, and hospital mortality rates than other patients in shock (Table 3) . No difference in ICU mortality rates in patients treated with dopamine was observed among university, city, and community hospitals (45.1%, 42.2%, and 36.1%, respectively, p ϭ .445). The degree of organ dysfunction, as assessed by the maximum and mean SOFA scores during the ICU stay, was similar among patients treated with dopamine and those who received no dopamine, as was hospital and ICU length of stay (Table 3) . Similar rates of renal support therapy were observed in both groups. A total of 284 (26.8%) patients stayed in the hospital for Ն30 days. The Kaplan-Meier survival curves are shown in Figure 2 . The 30-day survival was decreased in the dopamine group (log rank ϭ 4.6, p ϭ .032) compared with the nodopamine group. Epinephrine administration was also associated with a decreased 30 day-survival (log rank ϭ 14.4, p Ͻ .001).
Of 244 patients who were treated with both dopamine and norepinephrine, 141 (57.8%) received both drugs on the same first day, another 73 (29.9%) received norepinephrine as the first vasopressor treatment, and 30 (12.3%) received dopamine first. Mortality rates were 47.3%, 54.8%, and 53.3%, respectively (p ϭ not significant).
Predictors of ICU Outcome. Shock nonsurvivors (n ϭ 405) were older (Table 4) , were more commonly medical rather than surgical admissions, and were more likely to be female than the survivors. Comorbid diseases associated with a poor outcome included cancer, hematologic cancer, and liver cirrhosis. As expected, SAPS II and SOFA scores were higher in nonsurvivors. Although infection on admission was more common in nonsurvivors than survivors, ICU-acquired infection rates were similar in both groups. As expected, nonsurvivors required higher catecholamine doses. Dopamine and epinephrine were used more in nonsurvivors than in survivors. Cumulative and mean fluid balances were greater and ICU and hospital lengths of stay were longer in nonsurvivors than in survivors.
In a multivariate, logistic forward stepwise analysis with ICU outcome as the dependent factor, age, cancer, medical admission, higher mean SOFA score, greater mean fluid balance, and dopamine administration were independent risk factors for ICU mortality in patients with shock (Table 5 ). None of the tested interactions were significant and, there- fore, were not considered in the final model. Dopamine Use in Septic Shock. In the 462 patients with septic shock, dobutamine use was more common in nonsurvivors than in survivors (41.6% vs. 32.5%, p Ͻ .05). There was a tendency toward more epinephrine use (31.5% vs. 23.5%, p ϭ .052) and dopamine (43.4% vs. 35.4%, p ϭ .079) administration in nonsurvivors than in survivors. Also, there was a tendency toward lower 30-day survival (Fig. 3) in patients with septic shock treated with dopamine than others (log rank ϭ 2.8, p ϭ .09). Epinephrine administration was associated with decreased 30-day survival (log rank 4.04, p ϭ .045). However, norepinephrine and dobutamine administration was not associated with altered 30-day survival. Other factors associated with ICU mortality from septic shock included older age, female gender, cancer, hematologic cancer, medical admission, higher SAPS II and SOFA scores, and higher fluid balance ( Table 6 ). The ICU mortality rate in patients with septic shock was similar among patients admitted from a university, city, or community hospital (47.6%, 47.3%, 46.6%, respectively, p ϭ .989) with a similar incidence of dopamine administration (41.4%, 32.1%, 44.6%, respectively, p ϭ .127). In septic shock patients treated with dopamine, ICU mortality rates were also similar (52.2%, 54.8%, and 50%, respectively, p ϭ .925).
In a multivariate logistic forward stepwise analysis (Table 5) with ICU mortality as the dependent factor, dopamine administration was independently associated with a higher risk of death from septic shock (odds ratio, 2.05; 95% confidence interval, 1.25 -3.37), in addition to higher SOFA score, greater mean fluid balance, cancer, older age, and medical admission.
In patients with nonseptic shock (n ϭ 596), ICU (34% vs. 30%, p ϭ .303) and hospital (42% vs. 35%, p ϭ .117) mortality rates were higher, but statistically not significant, in patients who received dopamine compared with those who did not. In a multivariable logistic regression analysis with ICU mortality as the dependent variable, dopamine administration was not an independent risk factor for mortality in this group of patients (data not shown)
DISCUSSION
Our data suggest that dopamine administration may be associated with a worse outcome from shock due to any cause. Our study included almost 200 ICUs and Ͼ3,000 patients. One third of the patients had shock at some point during their ICU stay and 15% had septicshock. Dopamine was used in 35% of the patients with shock in these European ICUs.
Dopamine administration was associated with ICU and hospital mortality rates 20% higher than in patients with shock who did not receive dopamine; survival rates were also lower at 30 days than for other patients in shock. These differences could not be explained by differences in severity of disease, as SAPS II and SOFA scores on admission were similar in the two groups. Despite the relatively higher incidence of treatment with dopamine in ICUs located in community hospitals and the lower incidence in those located in city hospitals, this factor could not explain the worse outcome associated with dopamine use in this study as mortality rates were similar across hospital types not only in the whole population with shock but also in the subgroup with septic shock.
The use of norepinephrine did not show even a trend toward higher mortality in our patients. Patients treated with epinephrine had a worse outcome, but this agent is often given as a second-line agent in patients with more severe forms of cardiovascular failure. Also, dobutamine may be used more commonly for patients who have more severe myocardial depression (12) . However, the multivariable analysis identified dopamine as an independent risk factor for death in patients with shock due to any cause.
Our data cannot identify the reason for the increased mortality in dopaminetreated patients, but several hypotheses can be raised. First, dopamine may induce tachyarrhythmias. However, the increase in heart rate may contribute to the increase in cardiac output, thereby improving organ perfusion. The administration of dobutamine together with norepinephrine can also increase heart rate. Second, some investigators have suggested that norepinephrine may have more beneficial effects on gut mucosal perfusion than dopamine (7) . However, this statement is primarily based on a pilot study, suggesting a higher gastric intramucosal pH with norepinephrine than with dopamine, an observation that is debated (2, 13) . Experimental studies on this have yielded controversial results. Ruokonen et al. (14) found no changes in splanchnic blood flow or oxygen consumption with norepinephrine, whereas dopamine consistently increased splanchnic blood flow. More recently, De Backer et al. (2) found no differences in splanchnic blood flow or PCO 2 gap between norepinephrine and dopamine in 20 patients with septic shock. If anything, dopamine was associated with a lower mixed venous-hepatic venous oxygen saturation gradient, indicating a better oxygen balance with dopamine than norepinephrine (2) . Hence, it is unlikely that norepinephrine has more beneficial effects on gut mucosal perfusion than dopamine. Third, norepinephrine may have more beneficial effects on renal perfusion and more effectively restore urinary output (15) . On the other hand, the use of renal dose dopamine has been challenged for its lack of efficacy (16) and can no longer be recommended, although, interestingly, 23% of patients who received dopamine received doses Յ5 g/kg/min, suggesting that dopamine is still used in some ICUs for its supposed beneficial effects on renal function. We observed no difference in the need for renal support therapy in our study between dopamine-treated patients and other patients. Fourth, dopamine administration can reduce the release of a number of hormones from the anterior pituitary gland, including prolactin (17, 18) , which can have important immunoprotective effects. The tendency toward a higher incidence of ICU-acquired infection in dopamine-treated patients in our study may favor this mechanism. However, one may argue that if dopamine is used only for limited periods of time (as in shock resuscitation), the deleterious effects of this action may be transient and may even be beneficial in septic shock if the host response is exaggerated.
One report showed improved outcomes for patients in septic shock treated with norepinephrine (19) , but the nonrandomized, observational nature of that study means that the results must be interpreted with caution. No clinical study has definitely indicated that one catecholamine is superior to another, so that at present no agent should be preferred over the other (20, 21) .
Observational studies such as the current one have their limitations. The inclusion period was very short (2 wks) and participation was voluntary, so the results may not be extrapolated to all ICU patients. Moreover, the multivariable analyses cannot take all possible confounding factors into account, including organizational issues and differences in clinical practice (22) at the level of individual ICUs; the use of novel therapies that have proven efficacy in certain subsets of ICU patients, such as activated protein C (23) ; and the adoption of early goal-directed therapy (24) . Also, in cases of nonseptic shock, we were not able to discriminate between the various etiologies (anaphylactic, cardiac failure, etc), their management, and potential differences in their outcomes. We cannot determine a cause-and-effect relationship based on the current analysis. Nevertheless, this study suggests that dopamine administration may be associated with worse outcomes from shock of any cause. This observation needs further evaluation by a prospective, randomized, controlled study.
